Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.

Hongzhi Li,Weihua Yuan,Shufang Bin,Guang Wu,Panyuan Li,Min Liu,Jifeng Yang,Xiang Li,Kaiyan Yang,Haihua Gu

2022-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 688 in vol. 10, PMID: 32195036.].

What problem does this paper attempt to address?

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Jiaojiao Hao,Zhenglin Li,Changlin Zhang,Wendan Yu,Zhipeng Tang,Yixin Li,Xu Feng,Yue Gao,Quentin Liu,Wenlin Huang,Wei Guo,Wuguo Deng

DOI: https://doi.org/10.62347/suki5933

2024-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 13 in vol. 7, PMID: 28123844.].
Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Ru Zhou,Mahboubeh Yazdanifar,Lopamudra Das Roy,Lynsey M. Whilding,Artemis Gavrill,John Maher,Pinku Mukherjee

DOI: https://doi.org/10.3389/fimmu.2020.628776

IF: 7.3

2020-12-07

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2019.01149.].

immunology
Erratum to "Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple-Negative Breast Cancer Treatment"

Hongye He,Feng Li,Rui Tang,Nianhong Wu,Ying Zhou,Yuting Cao,Can Wang,Li Wan,Yang Zhou,Hua Zhuang,Pan Li

DOI: https://doi.org/10.34133/bmr.0088

2024-10-07

Abstract:[This corrects the article DOI: 10.34133/bmr.0064.].
Correction: An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts

Qing Chen,Ziyi Weng,Yunshu Lu,Yijun Jia,Longlong Ding,Fang Bai,Meixin Ge,Qing Lin,Kejin Wu

DOI: https://doi.org/10.1371/journal.pone.0311128

IF: 3.7

2024-09-23

PLoS ONE

Abstract:[This corrects the article DOI: 10.1371/journal.pone.0168960.].
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Jiang-Kai Dong,Hui-Min Lei,Qian Liang,Ya-Bin Tang,Ye Zhou,Yang Wang,Shengzhe Zhang,Wen-Bin Li,Yunguang Tong,Guanglei Zhuang,Liang Zhang,Hong-Zhuan Chen,Liang Zhu,Ying Shen

DOI: https://doi.org/10.7150/thno.58558

IF: 11.6

2021-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.23177.].

medicine, research & experimental
Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Qiuqiang Chen,Gang Jia,Xilin Zhang,Wenxue Ma

DOI: https://doi.org/10.3389/fimmu.2024.1376045

IF: 7.3

2024-01-31

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1332057.].

immunology
Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Hang-Ping Yao,Liang Feng,Sreedhar Reddy Suthe,Ling-Hui Chen,Tian-Hao Weng,Chen-Yu Hu,Eun Sung Jun,Zhi-Gang Wu,Wei-Lin Wang,Song Cheol Kim,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1186/s40425-019-0571-7

IF: 12.469

2019-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Following publication of the original article [1], the author reported two errors in the authors affiliations:
Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Zexi Hu,Yong Hu,Xicheng Liu,Rongwen Xi,Aiqun Zhang,Deruo Liu,Qiang Xie,Liang Chen

DOI: https://doi.org/10.18632/oncotarget.26252

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.5221.].
Erratum: CXCL12 Chemokine Expression Suppresses Human Breast Cancer Growth and Metastasis in Vitro and in Vivo.

Zhi-Dong Lv,Bin Kong,Xiang-Ping Liu,Qian Dong,Hai-Tao Niu,Yong-Hua Wang,Fu-Nian Li,Hai-Bo Wang

DOI: https://doi.org/10.62347/gevx3778

2024-01-01

Abstract:[This corrects the article on p. 6671 in vol. 7, PMID: 25400746.].
Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”

Haibo Xing,Mengting Tong,Jing Wang,Hanqing Hu,Chongya Zhai,Chunhui Huang,Da Li

DOI: https://doi.org/10.1155/2022/9767389

2022-01-01

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2018/3195025.].
Erratum: HOXC10 promotes carboplatin resistance of ovarian cancer by regulating ABCC3.

Yuanyuan Li,Han Lei,Rihan Hai,Guang Shu,Wenguang Yan,Gang Yin

2024-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 4602 in vol. 12, PMID: 36381312.].
Erratum: Addition and Correction to "High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles"

Kin Man Au,Rod Balhorn,Monique C Balhorn,Steven I Park,Andrew Z Wang

DOI: https://doi.org/10.1021/acscentsci.4c00703

2024-05-08

Abstract:[This corrects the article DOI: 10.1021/acscentsci.8b00746.].
Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer

DOI: https://doi.org/10.3233/BLC-219500

2021-03-19

Bladder Cancer

Abstract:[This corrects the article DOI: 10.3233/BLC-200013.].
Erratum: Overcoming immune resistance with radiation therapy in prostate cancer

DOI: https://doi.org/10.3389/fimmu.2023.1185185

IF: 7.3

2023-03-23

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.859785.].

immunology
Corrigendum to “Treatment-Related Adverse Events Associated with HER2-Targeted Antibody-Drug Conjugates in Clinical Trials: a Systematic Review and Meta-Analysis” [eclinicalmedicine 55 (2022) 101795]

Zhiwen Fu,Jinmei Liu,Shijun Li,Chen Shi,Yu Zhang

DOI: https://doi.org/10.1016/j.eclinm.2023.101908

IF: 15.1

2023-01-01

EClinicalMedicine

Abstract:[This corrects the article DOI: 10.1016/j.eclinm.2023.101904.][This corrects the article DOI: 10.1016/j.eclinm.2022.101795.].
Correction: Efficacy of transcatheter arterial chemoembolization for liver metastases arising from pancreatic cancer.

Jun-Hui Sun,Tan-Yang Zhou,Yue-Lin Zhang,Guan-Hui Zhou,Chun-Hui Nie,Tong-Yin Zhu,Sheng-Qun Chen,Bao-Quan Wang,Song Ye,Yan Shen,Hua Guo,Wei-Lin Wang,Shu-Sen Zheng

DOI: https://doi.org/10.18632/oncotarget.24759

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.14642.].
Erratum: Investigating tumor immunogenicity in breast cancer: deciphering the tumor immune response to enhance therapeutic approaches

Frontiers Production Office

DOI: https://doi.org/10.3389/fimmu.2024.1532921

IF: 7.3

2024-12-12

Frontiers in Immunology

Abstract:This article is an erratum on: Investigating tumor immunogenicity in breast cancer: deciphering the tumor immune response to enhance therapeutic approaches

immunology
Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Pengzhao Shang,Rui Gao,Yijia Zhu,Xiaorui Zhang,Yang Wang,Minji Guo,Hui Peng,Min Wang,Juan Zhang

DOI: https://doi.org/10.1016/j.apsb.2024.02.014

Abstract:[This corrects the article DOI: 10.1016/j.apsb.2020.09.008.].
Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan,Zhongzheng Zhu,Wei Mao,Hui Wang,Hong Qian,Jianguo Wu,Xianling Guo,Qing Xu

DOI: https://doi.org/10.3389/fonc.2021.796625

IF: 4.7

2022-01-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.683502.].

oncology
Erratum: N6-methyladenosine-induced ERRγ Triggers Chemoresistance of Cancer Cells Through Upregulation of ABCB1 and Metabolic Reprogramming: Erratum.

Zhuojia Chen,Long Wu,Jiawang Zhou,Xinyao Lin,Yanxi Peng,Lichen Ge,Cheng-Ming Chiang,Hui Huang,Hongsheng Wang,Weiling He

DOI: https://doi.org/10.7150/thno.85930

IF: 11.6

2023-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.40144.].

Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Erratum to "Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple-Negative Breast Cancer Treatment"

Correction: An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Erratum: CXCL12 Chemokine Expression Suppresses Human Breast Cancer Growth and Metastasis in Vitro and in Vivo.

Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”

Erratum: HOXC10 promotes carboplatin resistance of ovarian cancer by regulating ABCC3.

Erratum: Addition and Correction to "High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles"

Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer

Erratum: Overcoming immune resistance with radiation therapy in prostate cancer

Corrigendum to “Treatment-Related Adverse Events Associated with HER2-Targeted Antibody-Drug Conjugates in Clinical Trials: a Systematic Review and Meta-Analysis” [eclinicalmedicine 55 (2022) 101795]

Correction: Efficacy of transcatheter arterial chemoembolization for liver metastases arising from pancreatic cancer.

Erratum: Investigating tumor immunogenicity in breast cancer: deciphering the tumor immune response to enhance therapeutic approaches

Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Erratum: N6-methyladenosine-induced ERRγ Triggers Chemoresistance of Cancer Cells Through Upregulation of ABCB1 and Metabolic Reprogramming: Erratum.